New drug shows promise for controlling narcolepsy symptoms

NCT ID NCT06358950

Completed Disease control Sponsor: Alkermes, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested a new medication called ALKS 2680 for people with narcolepsy type 1. Researchers wanted to see if it could safely reduce daytime sleepiness and sudden muscle weakness (cataplexy) better than a placebo. The 92 participants took the drug or a placebo for 6 weeks while stopping their regular narcolepsy medications.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Alkermes Investigational Site

Los Angeles, California, 90025, United States
Alkermes Investigational Site

Redwood City, California, 94063, United States
Alkermes Investigational Site

Santa Ana, California, 92705, United States
Alkermes Investigational Site

Aurora, Colorado, 80045, United States
Alkermes Investigational Site

Colorado Springs, Colorado, 80918, United States
Alkermes Investigational Site

Brandon, Florida, 33511, United States
Alkermes Investigational Site

Miami, Florida, 33176, United States
Alkermes Investigational Site

Atlanta, Georgia, 30328, United States
Alkermes Investigational Site

Macon, Georgia, 31210, United States
Alkermes Investigational Site

Stockbridge, Georgia, 30281, United States
Alkermes Investigational Site

Middletown, New Jersey, 07748, United States
Alkermes Investigational Site

Denver, North Carolina, 28037, United States
Alkermes Investigational Site

Huntersville, North Carolina, 28708, United States
Alkermes Investigational Site

Cincinnati, Ohio, 45227, United States
Alkermes Investigational Site

Cincinnati, Ohio, 45245, United States
Alkermes Investigational Site

Dublin, Ohio, 43017, United States
Alkermes Investigational Site

Wyomissing, Pennsylvania, 19610, United States
Alkermes Investigational Site

Columbia, South Carolina, 29201, United States
Alkermes Investigational Site

Austin, Texas, 78731, United States
Alkermes Investigational Site

San Antonio, Texas, 78229, United States
Alkermes Investigational Site

The Woodlands, Texas, 77380, United States
Alkermes Investigational Site

Alken, 3570, Belgium
Alkermes Investigational Site

Bruges, 8000, Belgium
Alkermes Investigational Site

Namur, 5101, Belgium
Alkermes Investigational Site

Prague, 128 21, Czechia
Alkermes Investigational Site

Bordeaux, 33000, France
Alkermes Investigational Site

Montpellier, 34295, France
Alkermes Investigational Site

Bologna, 40139, Italy
Alkermes Investigational Site

Milan, 20127, Italy
Alkermes Investigational Site

Verona, 37134, Italy
Alkermes Investigational Site

Heemstede, 2103 SW, Netherlands
Alkermes Investigational Site

Zwolle, 8025 BV, Netherlands
Alkermes Investigational Site

Barcelona, 08036, Spain
Alkermes Investigational Site

Madrid, 28036, Spain
Alkermes Investigational Site

Madrid, 28043, Spain
Alkermes Investigator Site

San Francisco, California, 94107, United States
Alkermes Investigator Site

Brandon, Florida, 33511, United States
Alkermes Investigator Site

Winter Park, Florida, 32789, United States
Alkermes Investigator Site

Peoria, Illinois, 61637, United States
Alkermes Investigator Site

Lansing, Michigan, 48911, United States
Alkermes Investigator Site

Sterling Heights, Michigan, 48314, United States
Alkermes Investigator Site

Lincoln, Nebraska, 68506, United States
Alkermes Investigator Site

Canton, Ohio, 44718, United States
Alkermes Investigator Site

Macquarie Park, New South Wales, 2113, Australia
Alkermes Investigator Site

Bedford Park, South Australia, 5042, Australia

Conditions

Explore the condition pages connected to this study.

NARCOLEPSY TYPE 1